ORKA Oruka Therapeutics, Inc.

NEUTRAL Impact: 3/10 Insider Cluster (2 insiders)
Horizon days Filed May 18, 2026 Processed 25d 13h ago
Insider cluster: 2 insiders, $540K total
Latest settled — T+5d
ORKA ▲ +0.85% at T+5d
NEUTRAL call ✓ call won +0.85% · α vs SPY -1.44% · entry $57.50 → $57.99
Next anchor: T+20d in 3d
Currently $69.89 · +21.55% from $57.50 entry
Entry anchored
May 18, 2026
via day open
T+1d
+5.51%
call +5.51% · α +4.47%
$60.67
settled 25d ago
T+5d
+0.85%
call +0.85% · α -1.44%
$57.99
settled 18d ago
T+20d
call — · α —
in 3d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Two senior insiders at Oruka Therapeutics (CMO & SVP Finance) collectively sold ~$540K of stock on May 15-18, 2026, following derivative exercises. This represents only ~0.015% of the $3.7B market cap — a trivial dollar value relative to company size. Cluster insider SALES are not amplified by cross-filing context but the absolute materiality is negligible, making this a routine liquidity/vesting event rather than an informed signal.

Key Financial Metrics

Direction
selling
Total Value
$540.0K
Insiders
2

Actionable Insight

Sales are quantitatively trivial and structurally typical of post-vesting tax-related liquidation. Flush with institutional bullishness (95% analyst buy rating) and a ~$3.7B market cap, this insider activity provides no credible trading signal. No action warranted; monitor any future large-scale C-suite selling or 10b5-1 establishment.

Key Facts

  • CMO Joana Goncalves sold 4,800 shares at $61.56 for $295K on May 15
  • SVP Finance Arjun Agarwal sold 4,190 shares at $58.34 for $244K on May 18
  • Both sales followed derivative exercises (options/RSAs) — indicative of tax-covering liquidity sales
  • Total cluster value $540K = ~0.015% of $3.7B market cap
  • No C-suite CEO/CFO participation; both are second-tier executives one level below C-suite

Financial Impact

Cluster sale value of ~$540K represents 0.015% of market cap — well below 0.1% threshold for materiality

dilution

Risk Factors

  • Potential further insider sales if share price continues to weaken from May highs
  • No CEO or CFO participation could suggest management confidence remains intact

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ORKA-1779142117031
13 reports for ORKA
Performance horizon
83% Hit rate 5 of 6 directional calls best @ T+20▲ +20.18%Apr 27, 2026
Filters
Rows
Reports for ORKA — sortable, filterable
Type Now
Jun 11, 2026
2d ago
Institutional Cluster
NEUTRAL ★ 3/10
$63.94 awaiting T+1awaiting T+1$69.89 (+9.31%)
Jun 1, 2026
11d ago
8-K
BULLISH ★ 7/10
$55.23 $57.20▲ +3.57%▲ +4.26%$69.89 (+26.54%)
May 22, 2026
21d ago
Insider Cluster
NEUTRAL ★ 3/10
$59.06 $57.99▼ −1.81%▼ −1.82%$69.89 (+18.34%)
May 18, 2026
25d ago
Insider Cluster
NEUTRAL ★ 3/10
$57.50 $60.67▲ +5.51%▲ +4.47%$69.89 (+21.55%)
Apr 28, 2026
6w ago
Press Release
BEARISH ★ 6/10
$68.10 $68.10· 0.00%▲ +1.02%$69.89 (−2.63%)
Apr 27, 2026
6w ago
424B5
BEARISH ★ 7/10
$73.99 $69.49▲ +6.08%▲ +6.07%$69.89 (+5.54%)
Apr 27, 2026
6w ago
Press Release
BEARISH ★ 6/10
$73.99 $69.49▲ +6.08%▲ +6.07%$69.89 (+5.54%)
Apr 27, 2026
6w ago
8-K
BULLISH ★ 8/10
$76.39 $73.99▼ −3.14%▼ −2.66%$69.89 (−8.51%)
Apr 17, 2026
8w ago
DEFA14A
NEUTRAL ★ 3/10
$68.87 $69.00▲ +0.19%▲ +0.84%$69.89 (+1.48%)
Apr 15, 2026
8w ago
144
NEUTRAL ★ 3/10
$67.07 $68.92▲ +2.76%▲ +1.54%$69.89 (+4.20%)
Showing 10 of 13

US Market Status

Market Closed — Opens Mon (49h 37m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access